Jane A.
Jane A. Cowee, Kansas City, MO US
Patent application number | Description | Published |
---|---|---|
20100292268 | Formulations Containing Clopidogrel and Sulfoalkyl Ether Cyclodextrin and Methods of Use - The present invention provides compositions containing clopidogrel, present as a free base or a pharmaceutically acceptable salt thereof, and sulfoalkyl ether cyclodextrin (SAE-CD). The compositions can be liquid, suspension or solid compositions. They can be adapted for oral, peroral or parenteral administration. The SAE-CD serves to aid in dissolution and stabilization of the clopidogrel in aqueous media. The stability of clopidogrel against hydrolytic degradation, thermal degradation, and photolytic degradation are improved. SAE-CD provides improved results over other cyclodextrin derivatives. The SAE-CD-containing composition of clopidogrel can be provided in liquid form, solid form or as a reconstitutable powder. Both ready-to-use and concentrated liquid compositions can be prepared. The liquid composition is optionally available as a clear solution. The compositions herein can be administered perorally or parenterally and provide substantial pharmacokinetic, pharmacodynamic and/or therapeutic advantages over a tablet composition administered perorally and excluding SAE-CD. | 11-18-2010 |
20130129700 | FORMULATIONS CONTAINING CLOPIDOGREL AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USE - The present invention provides compositions containing clopidogrel, present as a free base or a pharmaceutically acceptable salt thereof, and sulfoalkyl ether cyclodextrin (SAE-CD). The compositions can be liquid, suspension or solid compositions. They can be adapted for oral, peroral or parenteral administration. The SAE-CD serves to aid in dissolution and stabilization of the clopidogrel in aqueous media. The stability of clopidogrel against hydrolytic degradation, thermal degradation, and photolytic degradation are improved. SAE-CD provides improved results over other cyclodextrin derivatives. The SAE-CD-containing composition of clopidogrel can be provided in liquid form, solid form or as a reconstitutable powder. Both ready-to-use and concentrated liquid compositions can be prepared. The liquid composition is optionally available as a clear solution. The compositions herein can be administered perorally or parenterally and provide substantial pharmacokinetic, pharmacodynamic and/or therapeutic advantages over a tablet composition administered perorally and excluding SAE-CD. | 05-23-2013 |
20150025243 | FORMULATIONS CONTAINING CLOPIDOGREL AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USE - The present invention provides compositions containing clopidogrel, present as a free base or a pharmaceutically acceptable salt thereof, and sulfoalkyl ether cyclodextrin (SAE-CD). The compositions can be liquid, suspension or solid compositions. They can be adapted for oral, peroral or parenteral administration. The SAE-CD serves to aid in dissolution and stabilization of the clopidogrel in aqueous media. The stability of clopidogrel against hydrolytic degradation, thermal degradation, and photolytic degradation are improved. SAE-CD provides improved results over other cyclodextrin derivatives. The SAE-CD-containing composition of clopidogrel can be provided in liquid form, solid form or as a reconstitutable powder. Both ready-to-use and concentrated liquid compositions can be prepared. The liquid composition is optionally available as a clear solution. The compositions herein can be administered perorally or parenterally and provide substantial pharmacokinetic, pharmacodynamic and/or therapeutic advantages over a tablet composition administered perorally and excluding SAE-CD. | 01-22-2015 |
Jane A. Faver, Little Rock, AR US
Patent application number | Description | Published |
---|---|---|
20090302105 | Automated dry cleaning delivery system - An automated, self-service dry cleaning delivery system accepts and records items dropped off through a kiosk for cleaning, and returns cleaned items to the same kiosk for customer pick-up. A computer software program operates the conveyors, the loading doors, and material transporting equipment. To facilitate maximum customer satisfaction, numerous customer feedback choices are displayed to maximize system dexterity. | 12-10-2009 |
Jane A. Groos, Seattle, WA US
Patent application number | Description | Published |
---|---|---|
20100297063 | CYTOKINE ZALPHA11 LIGAND ANTIBODIES - Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller polypeptide and peptide sequences. The antibodies may include antibodies that are polyclonal, monoclonal, murine, humanized or neutralizing. Methods for producing the antibodies are also described. | 11-25-2010 |
Jane A. Hoxsey, Wenatchee, WA US
Patent application number | Description | Published |
---|---|---|
20130233036 | MINERAL-RELEASING COMPOST AND METHOD OF USING THE SAME FOR SOIL REMEDIATION - Described herein is a mineral-releasing compost prepared by combining a prebiotic material, a probiotic material, and one or more mineral gluconate salts to form a composting mixture, controlling composting conditions to allow for the composting mixture to decompose, and allowing the composting mixture to fully stabilize and mature, wherein the compost includes one or more minerals as digested products of the respective mineral gluconate salts. The mineral-releasing compost is particularly suitable for remediation of soil contaminated with heavy metals and for amendment of soil deficient of certain minerals. | 09-12-2013 |
Jane A. Mckeating, Birmingham GB
Patent application number | Description | Published |
---|---|---|
20080241156 | Inhibitors of hepatitis C virus - The present invention relates to methods that employ peptides or peptide derivatives to inhibit hepatitis C virus infection. The present invention is based in part on the discovery that E2 envelope glycoprotein of hepatitis C virus has previously undescribed domains that are important for interactions with cellular or viral proteins that are necessary for early steps in HCV infection. The present invention provides peptides and methods of treatment and prophylaxis of diseases induced by hepatitis C virus and related viruses. | 10-02-2008 |
20090209464 | Flavivirus fusion inhibitors - The present invention relates to peptides and methods of inhibiting fusion between the virion envelope of Flaviviruses and membranes of the target cell, the process that delivers the viral genome into the cell cytoplasm. The invention provides for methods which employ peptides or peptide derivatives to inhibit Flavivirus:cell fusion. The present invention is based in part on the discovery that E1 envelope glycoprotein of hepaciviruses and E2 envelope glycoprotein of pestivirus have previously undescribed structures, truncated class II fusion proteins. The present invention provides peptides and methods of treatment and prophylaxis of diseases induced by Flaviviruses. | 08-20-2009 |
Jane A. Mckeating, New York, NY US
Patent application number | Description | Published |
---|---|---|
20110130328 | FLAVIVIRUS FUSION INHIBITORS - The present invention provides an isolated peptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:36, as well as derivatives thereof comprising various N-terminal and C-terminal chemical moieties, substituted analogs thereof, and fragments thereof. The peptides of the invention are useful for treating and preventing a Flavivirus invention. Pharmaceutical compositions comprising the peptides, and methods of treating or preventing Flavivirus infections, are also provided. | 06-02-2011 |
Jane A. Murray, Muncie, IN US
Patent application number | Description | Published |
---|---|---|
20150121958 | Interlocking Ring System and device with Interchangeable Outer Jackets and Center Rings called a TULIP. - A jewelry ring configuration having interchangeable elements and especially jewelry rings which have a decorative feature mounted on a center ring. This new device/process may be simply described as a device for an interlocking ring system and device with interchangeable outer jackets and center rings comprised with a center ring, ornate and decorative or smooth and with or without gemstones, the center ring in various mounting styles such as prong, bezel, pave etc.; and a jacket as an outer band, held together by one or more straps, the jacket being ornate and with or without gemstones and made of the same, complimentary or contrasting materials as the center ring wherein the interchangeable outer jackets and center rings provide an interchangeable, stylish combination of interlocking jackets and center rings. | 05-07-2015 |
Jane A. Skeeter, West Hills, CA US
Patent application number | Description | Published |
---|---|---|
20100221565 | Recycled Glass Structural and Decorative Barrier or Building, Lighting and Furniture Component - A decorative structure comprises a frame completely surrounding a space and a front and rear barrier material applied to front and rear surfaces of the frame enclosing the space to form a three dimensional structure. The space located between the front and rear barrier material and the frame, is filled with pieces of waste glass, or other recycled material, which has been processed to have smoothened surfaces and provide a decorative appearance. At least the front barrier material has sufficient transparency so that the decorative appearance of the waste material held behind the barrier is visible. | 09-02-2010 |
Jane A. Thomas, Oxnard, CA US
Patent application number | Description | Published |
---|---|---|
20100137747 | CLINICAL ASSESSMENT SCALES AND METHODS - Disclosed herein are scales for assessing lip fullness, severity of perioral lines at rest, severity of perioral lines at maximum contraction or oral commissures. The scales comprise rows or columns of photographs corresponding to different severity categories. Each scale may have a Kappa score of at least about 0.700 for intra-rater and inter-rater reliability. | 06-03-2010 |
20110160617 | CLINICAL ASSESSMENT SCALES AND METHODS - Disclosed herein are scales for assessing lip fullness, severity of perioral lines at rest, severity of perioral lines at maximum contraction or oral commissures. The scales comprise rows or columns of photographs corresponding to different severity categories. Each scale may have a Kappa score of at least about 0.700 for intra-rater and inter-rater reliability. | 06-30-2011 |